Commencement Of Pivotal Phase IV Clinical Study: The Team Behind The Scene
- The Company Has Lined Up A Strong Team To Support The Study
KUALA LUMPUR, 18 NOVEMBER 2020 – Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code:9601) has begun its Phase IV clinical study on COVID-19 vaccine with E-MO Biology Inc (“EBI”) whose key business revolves around biology research and development activities besides indicating booster polio vaccine can reduce COVID-19 SARS-COV-2 infection and severity.
The Phase IV clinical study will be led by EBI founder and managing director, Dr. Xie Qiyi (“Dr. Xie”).
HWGB BIOTECH SDN BHD (Formerly known as HWG Consortium Sdn Bhd) [Company Number: 201201022032 (1006524-T)]